公开(公告)号：US20250017864A1

公开(公告)日：2025-01-16

申请号：US18705759

申请日：2022-10-28

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Hozefa Bandukwala ,  Susan J. Drapeau ,  Lauren E. Jansen

IPC: A61K9/50 ,  A61K35/30 ,  A61K45/06 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26

Abstract: Described herein are hydrogel capsule compositions which comprise a population of hydrogel capsules and a pharmaceutically acceptable solution. The hydrogel capsules in the population comprise a hydrogel-forming polymer and encapsulate a plurality of cells.

公开(公告)号：US20250000788A1

公开(公告)日：2025-01-02

申请号：US18274134

申请日：2022-01-26

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Sofia Brites Boss ,  Christopher P. Hencken ,  Hozefa Bandukwala ,  Robert James Miller ,  Omid Veiseh ,  Devyn McKinley Smith

IPC: A61K9/00 ,  A61K9/50 ,  A61K31/5685 ,  A61K31/573 ,  A61K31/58 ,  A61K35/545 ,  A61K38/13 ,  A61K38/17 ,  A61K38/20 ,  A61K47/61 ,  A61K47/69

Abstract: Described herein are implantable devices comprising living cells and an extended release formulation of a glucocorticoid.

公开(公告)号：US20230233679A1

公开(公告)日：2023-07-27

申请号：US17923283

申请日：2021-05-04

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Hozefa Bandukwala ,  David E. Moller ,  David Peritt

IPC: A61K39/00 ,  A61K9/00 ,  A61K39/39 ,  A61K39/215 ,  A61K39/21 ,  A61K39/245 ,  A61K39/155 ,  A61K9/48 ,  A61K9/06

CPC classification number: A61K39/4634 ,  A61K39/4635 ,  A61K9/0024 ,  A61K39/39 ,  A61K39/215 ,  A61K39/21 ,  A61K39/245 ,  A61K39/155 ,  A61K9/4808 ,  A61K9/06 ,  A61K9/4866 ,  A61K2039/55522

Abstract: Described herein are implantable devices comprising cells engineered to express and secrete antigens of infectious agents. The devices are useful for inducing protective immune responses against infectious agents.

公开(公告)号：US20240374507A1

公开(公告)日：2024-11-14

申请号：US18274125

申请日：2022-01-26

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Sofia Brites Boss ,  Hozefa Bandukwala

IPC: A61K9/00 ,  A61K9/50 ,  A61K35/30 ,  A61K39/00 ,  A61P37/06 ,  C12N5/00

Abstract: Described herein are implantable devices configured to continuously deliver one or more antigens in combination with one or more immunosuppressive agents. The devices may be useful for inducing antigen-specific immune tolerance to the delivered antigen(s) and for reducing or preventing anti-drug antibody responses when delivering therapeutic substances.

公开(公告)号：US20240307455A1

公开(公告)日：2024-09-19

申请号：US18274123

申请日：2022-01-26

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Sofia Brites Boss ,  Christopher P. Hencken ,  Hozefa Bandukwala

IPC: A61K35/36 ,  A61K9/48 ,  A61K31/436 ,  A61K31/573 ,  A61K45/06 ,  A61P37/06 ,  C12N5/00

CPC classification number: A61K35/36 ,  A61K9/4808 ,  A61K31/436 ,  A61K31/573 ,  A61K45/06 ,  A61P37/06 ,  C12N5/0012 ,  C12N2510/00

Abstract: Described herein are implantable devices comprising cells genetically modified to express and secrete one or more immunomodulatory proteins. The devices and compositions thereof may be useful for treating immune-mediated inflammatory diseases.